Neumora Therapeutics Securities Class Action
Analysis based on 56 articles · First reported Feb 11, 2025 · Last updated Apr 03, 2025
The class action lawsuit against Neumora Therapeutics for alleged securities fraud could lead to significant financial penalties and reputational damage for the company, potentially impacting its stock price. Investors who purchased Neumora Therapeutics common stock during the class period may recover losses if the lawsuit is successful.
Neumora Therapeutics, a publicly traded company, is facing multiple securities class action lawsuits filed by law firms including Kessler Topaz Meltzer & Check, The Gross Law Firm, and Levi & Korsinsky. The lawsuits allege that Neumora Therapeutics made materially false and/or misleading statements in its initial public offering (IPO) documents, issued around September 15, 2023. Specifically, the complaints claim that Neumora Therapeutics amended the Phase Two trial inclusion criteria for its therapeutic candidate, Navacaprant, to include patients with moderate to severe Major Depressive Disorder (MDD) and added a prespecified analysis to the statistical plan to show statistically significant improvement in treating MDD. Furthermore, it is alleged that the Phase Two Trials lacked adequate data, particularly concerning patient population size and gender ratio, to accurately predict the results of the KOASTAL-1 study. The lawsuits are filed in the United States — United States District Court for the Northern District of California, and the lead plaintiff deadline for investors is April 7, 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard